Patrick C. Ma, MD, MS

Aerodigestive Oncology Translational Research THOR, Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

Dr. Patrick C. Ma joined West Virginia University Mary Babb Randolph Cancer Center in Morgantown, WV, USA in December 2014 where he was appointed to be the co-leader of the endowed Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program, Eminent Scholar in Lung Cancer Research, and Associate Professor of Medicine. Prior to WVU, he held the position as Director of Aerodigestive Oncology Translational Research Program and Staff Thoracic Oncologist at the Taussig Cancer Institute, Cleveland Clinic in Ohio, USA from 2010-2014. Dr. Ma also previously worked as Assistant Professor of Medicine at the Case Western Reserve University/University Hospitals Case Medical Center (2005-2010); and Attending Physician and Instructor of Medicine at the University of Chicago Pritzker School of Medicine (20032005). Dr. Ma graduated his medical education (M.D.) at the University of Toronto, Ontario, Canada, where he also completed postgraduate studies in Biochemistry and Family Medicine board certification, before relocating in 1996 to Boston, U.S. Subsequently, Dr. Ma further completed his Internal Medicine residency and then subspecialty postgraduate fellowship training in Hematology-Oncology at Tufts-New England Medical Center, and also Thoracic Oncology Research Fellowship at Dana-Farber Cancer Institute in Boston, MA.

Dr. Ma has a special interest in thoracic malignancies including lung cancer and mesothelioma. He leads laboratory-based translational and clinical research in aerodigestive oncology, with an emphasis on cancer genomics, cancer metabolomics and personalized molecularly-targeted therapies. Dr. Ma’s particular research focuses include oncogenic kinase signaling, mutational analysis and profiling of molecular/genomic therapeutic targets of lung cancer, and also genomic determinants of precision therapy sensitivity and resistance. He has considerable expertise in MET/HGF targeting therapy in lung cancer. Through his research endeavors, he has been awarded a number of competitive awards and research grants. Dr. Ma has also been named Best Doctor (Medical Oncology) by the Cleveland Magazine 2013-2014. Dr. Ma is principal investigator or co-investigator in several lung cancer clinical trials investigating novel targeted therapeutics in lung cancer. He is recipient of research grant support from NIH/NCI-K08 and more recently from Department of Defense (DOD) Lung Cancer Promising Clinician Research Award. Dr. Ma has also authored and co-authored numerous peer-reviewed articles and abstracts, reviews and book chapters, and has previously presented at national and international scientific conferences in thoracic oncology.